Title
TGRL Lipolysis Products Induce Stress Protein ATF3 via the TGF-β Receptor Pathway in Human Aortic Endothelial Cells.

Permalink
https://escholarship.org/uc/item/03v5j52q

Journal
PloS one, 10(12)

ISSN
1932-6203

Authors
Eiselein, Larissa
Nyunt, Tun
Lamé, Michael W
et al.

Publication Date
2015

DOI
10.1371/journal.pone.0145523

Peer reviewed
TGRL Lipolysis Products Induce Stress Protein ATF3 via the TGF-β Receptor Pathway in Human Aortic Endothelial Cells

Larissa Eiselein¹, Tun Nyunt¹, Michael W. Lamé², Kit F. Ng¹, Dennis W. Wilson³, John C. Rutledge¹, Hnin H. Aung¹*

¹ Department of Internal Medicine, Division of Cardiovascular Medicine, School of Medicine, University of California Davis, Davis, California, 95616, United States of America, ² Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, California, 95616, United States of America, ³ Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, 95616, United States of America

* mhaung@ucdavis.edu

Abstract

Studies have suggested a link between the transforming growth factor beta 1 (TGF-β1) signaling cascade and the stress-inducible activating transcription factor 3 (ATF3). We have demonstrated that triglyceride-rich lipoproteins (TGRL) lipolysis products activate MAP kinase stress associated JNK/c-Jun pathways resulting in up-regulation of ATF3, pro-inflammatory genes and induction of apoptosis in human aortic endothelial cells. Here we demonstrate increased release of active TGF-β at 15 min, phosphorylation of Smad2 and translocation of co-Smad4 from cytosol to nucleus after a 1.5 h treatment with lipolysis products. Activation and translocation of Smad2 and 4 was blocked by addition of SB431542 (10 μM), a specific inhibitor of TGF-β-activin receptor ALKs 4, 5, 7. Both ALK receptor inhibition and anti TGF-β1 antibody prevented lipolysis product induced up-regulation of ATF3 mRNA and protein. ALK inhibition prevented lipolysis product-induced nuclear accumulation of ATF3. ALKs 4, 5, 7 inhibition also prevented phosphorylation of c-Jun and TGRL lipolysis product-induced p53 and caspase-3 protein expression. These findings demonstrate that TGRL lipolysis products cause release of active TGF-β and lipolysis product-induced apoptosis is dependent on TGF-β signaling. Furthermore, signaling through the stress associated JNK/c-Jun pathway is dependent on TGF-β signaling suggesting that TGF-β signaling is necessary for nuclear accumulation of the ATF3/c-Jun transcription complex and induction of pro-inflammatory responses.

Introduction

Although the exact regulatory mechanisms are not yet understood, many studies have found increased apoptotic signals in vascular cells of atherosclerotic plaques compared to normal vessels [1–4]. Well-known risk factors for the development of atherosclerosis, such as high glucose...
levels [5], increased oxidative stress, angiotensin II [6] and oxidized low-density lipoprotein (LDL) [7] have all been shown to induce apoptosis in endothelial cells.

Triglyceride-rich lipoproteins (TGRL) include chylomicrons, which contain triglycerides derived from the exogenous (intestine-derived) pathway, and VLDL (very low-density lipoprotein), which contain triglycerides from the endogenous (liver-derived) pathway. Lipolysis of TGRL occurs when lipoproteins bind to lipoprotein lipase (LpL) [8], an enzyme anchored to the surface of endothelial cells [9, 10]. While cultured endothelial cells lack surface LpL, we have modeled the effects of TGRL lipolysis using pre-treatment of postprandial lipids isolated from humans with exogenous LpL. TGRL lipolysis releases neutral and oxidized free fatty acids (FFAs) that induce endothelial cell inflammation in high physiological and pathophysiological concentrations and injure endothelial cells by increasing VLDL remnant deposition in the artery wall [11, 12], augment endothelial monolayer permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis [13]. TGRL lipolysis products also significantly increase the production of reactive oxygen species (ROS) in endothelial cells and alter lipid raft morphology [11]. Pro-inflammatory pathways are activated and predominate when endothelial cells are exposed to high physiological and pathophysiological concentrations of TGRL lipolysis products, but not TGRL alone [14–16]. We recently reported that TGRL lipolysis products activate stress response pathways that induce expression of multiple pro-inflammatory and pro-apoptotic genes leading to endothelial dysfunction [17]. We identified transcription of ATF3, a member of the CREB family, as a key response gene after treatment with TGRL lipolysis products and demonstrated that its induction was essential for the expression of a subset of pro-inflammatory responses. The signaling mechanisms behind these phenomena, however, are not well understood.

Activating transcription factor 3 (ATF3) is both constitutively expressed and induced by a variety of signaling pathways. ATF3 binds to a variety of AP-1 sequence promoter sites as a homodimer or as a heterodimer with other members of the AP-1 transcription factor family such as c-Jun [18]. ATF3 appears to play a complex central role in modulating pro-inflammatory responses as ATF3 deficient mice are more susceptible to sepsis [19] and ventilator induced lung injury [20]. Further, a variety of stress-stimuli, which are also known risk factors for the development of atherosclerosis, can rapidly induce ATF3 in endothelial cells. These include ox LDL, homocysteine, TNF-α or palmitate [21]. Our findings demonstrated that ATF3 induction by products of TGRL lipolysis was dependent on the stress response MAP kinase pathway acting through JNK and c-Jun [17].

TGF-β1 is released from a secreted latent complex and is involved in many different biological processes, such as cell growth, cell cycle progression, migration, differentiation, matrix production and apoptosis [22, 23]. Studies have shown that in vascular endothelial cells, TGF-β1 is a potent inducer of apoptosis [24, 25]. TGF-β1 signaling occurs when specific type I and type II serine/threonine kinase receptors form heteromeric complexes [26]. The type I receptor, also termed activin receptor-like kinase (ALK), is then phosphorylated by the constitutively active TGF-β type II receptor (TβR-II). Although several ALKs and type II receptors exist in vertebrates, the typical receptor combination for TGF-β1 signaling is ALK-5/TβR-II. Second messenger activation occurs when phosphorylated ALK in turn phosphorylates receptor-regulated Smads (R-Smads). Phosphorylation of Smad2 and Smad3 proteins results in dissociation from the receptor and binding to the common mediator Smad4. The Smad-complex then translocates to the nucleus where it regulates transcription of target genes by interacting with many specific DNA-binding proteins.

Several studies have shown that the TGF-β1/Smad cascade is closely linked to the p53 signaling network [27–29] and that TGFβ-1 can increase p53 expression in various cell types [30]. p53 protein is a transcription factor that regulates the expression of a wide variety of genes...
involved in cell cycle arrest and apoptosis in response to genotoxic or cellular stress. Our previous study [17] and others [31, 32] had shown that JNK activates ATF3 through transcriptional regulation. JNK activation also results in phosphorylation of c-Jun which in turn can form a complex with ATF3 with subsequent binding to AP-1 responsive promoter regions. While both ATF3 and c-Jun promote apoptosis [33], this is opposed by JunB, another transcription factor activated through the NFκB pathway.

Oxidized LDL, a mediator for the development of atherosclerotic cardiovascular disease, has been demonstrated to activate the TGFβ-1/Smad signaling cascade in glomerular mesangial cells [34, 35] and is known to be a potent inducer of apoptosis in endothelium [7, 36–38]. Like oxidized LDL, lipolysis products generated from the hydrolysis of triglyceride-rich lipoproteins (TGRL), are now increasingly appreciated as active participants in the development of atherosclerosis.

Recent studies have suggested that ATF3 up-regulation and activity as a transcription factor can be controlled by, and depends on, prior TGFβ receptor activation. In epithelial cells, TGF-β stimulation has been shown to rapidly induce the expression of ATF3 via a Smad3 containing transcriptional complex [39]. Furthermore, ATF3, in turn, has been shown to directly interact and complex with Smad3 and Smad4 to act as a transcriptional repressor [39]. Our prior studies demonstrating TGRL lipolysis products induce endothelial cell apoptosis suggested a potential role for TGF-β in the response. Here, we test the hypothesis that the observed lipolysis product-induced up-regulation and activation of ATF3 in HAEC is regulated by the TGF-β signaling system.

**Materials and Methods**

**Human TGRL isolation**

The protocol for obtaining human TGRL (Protocol No. 223062) was approved by the Human Subjects Review Committee/IRB at the University of California Davis. The participants were written informed consent to participate in this study. The informed consent was also approved by the ethics committees/IRB. Postprandial blood samples were obtained 3.5 h after consumption of a moderately high fat meal, which corresponds to the peak elevation in plasma triglyceride concentrations. TGRL were isolated from human plasma at a density of less than 1.0063 g/mL following an 18 h centrifugation at 40,000 rpm in a SW41 Ti swinging bucket rotor (Beckman Coulter, Sunnyvale, CA) held at 4°C within a Beckman L8-70M (Beckman) ultracentrifuge. The top fraction TGRL was collected and dialyzed in Spectrapor membrane tubing (mol wt cut off 3,500; Spectrum Medical Industries, Los Angeles, CA) at 4°C overnight against a saline solution containing 0.01%EDTA. The TGRL lipolysis mix routinely used in experiments was normalized based on triglyceride concentrations and was diluted to contain 150 mg/dL of triglycerides. Total triglyceride content of samples was determined using the serum triglyceride determination kit (Sigma Aldrich cat # TR0100). The kit converts triglycerides to free fatty acids and glycerol and glycerol is assayed enzymatically.

**Reagents and antibodies**

Lipoprotein lipase (LpL) (L2254), monoclonal anti-β-actin antibody (A 5441), and an inhibitor of activin receptor-like kinases (ALKs 4, 5, and 7), SB 431542 (ALK) were purchased from Sigma, St. Louis, MO. Human TGF-β1 (100B) and recombinant human TGF-β1 (anti TGF-β1 antibody) (MAB240) from R&D Systems Inc., Minneapolis, MN. Antibodies were purchased from the following sources: phospho-Smad2/3 (Ser423/425) (sc-11769-R), Smad4 (sc-7154), ATF3 (sc-188), c-Jun (sc-1694), p53 (sc-6243) and CD-36 (sc-5523) from Santa Cruz Technology, Santa Cruz, CA; Smad2 (#3103), p-Smad2 (Ser465/467)/Smad3 (Ser423/425) (#8828)
and p-c-Jun (#9261) from Cell Signaling Technology (Danvers, MA); caspase-3 (IMG-144A) from (Imgenex, San Diego, CA); Nuclear Loading Control Anti-TATA binding protein TBP antibody (ab63766) from Abcam (Cambridge, MA); HRP-conjugated secondary anti-mouse (Amersham # NXA931) or anti-rabbit antibody (Amersham #NA9340V) from GE-Biosciences. Isotype control for rabbit IgG (AB-105-C) and mouse IgG (MAB-002) were purchased from R & D system, Minneapolis, MN. Secondary Goat anti-rabbit antibody conjugated to Alexa fluor 488 (A-11034) was purchased from Molecular Probes, Eugene, OR.

Cell culture and lipid treatments

Human aortic endothelial cells (HAEC) (passage 6, Cascade Biologics, Portland, OR) were cultured in EBM-2 basal media (cc-3156) supplemented with EGM-2 SingleQuot Kit (cc-4176) (Lonza, Walkersville MD) under and atmosphere of 5% CO2: 95% air at 37°C. Cells were exposed to the following conditions, media, TGRL (150 mg/dL = 1.5 mg/mL), lipoprotein lipase (LpL) (2 U/mL), and TGRL lipolysis product (TGRL (150 mg/dL) + LpL (2 U/mL)). The final concentration of TGRL, LpL, and TGRL lipolysis products were diluted in media and pre-incubated for 30 minute at 37°C prior to application. For positive control, cells were treated with 20 ng/mL of human TGF-β1 for 3 h. To study the involvement of TGF-β signaling, following co-incubation experiments were performed. ALK, SB 431542 (10 μM) and 4 μg/mL of anti TGF-β1 antibody were co-incubated with HAEC and TGRL lipolysis products for 3 h. To test the CD36 receptor binding to FFAs from TGRL lipolysis products, CD36 receptor blocking antibody (2 μg/mL) was co-incubated with TGRL lipolysis products for 3 h. After incubation, cells were washed with cold PBS and harvested based on experimental endpoints.

mRNA and protein expression were analyzed at the following time points: TGF-β1 release at 15 min, 30 min and 45 min; p-Smad2/3 and Smad2 protein expression at 1.5 h; Smad4 translocation at 1, 2 and 3 h; p53 protein expression at 0.5, 1.5 and 3 h; ATF3, p-c-Jun, caspase-3 protein expression and mRNA expression of ATF3, IL-8, E-selectin, JunB, IL-6, NFKB1 (NFκB) and NFKBIA (IκBA) at 3 h.

TGF-β1 Immunoassay

HAEC were grown to confluence in 6-well medical grade polystyrene plates (BD Falcon, Franklin Lakes, NJ) and were then stimulated with media control (M) or TGRL (T, 150 mg/dL) alone, LpL (L, 2 U/mL) alone or TGRL lipolysis products (TL, TGRL plus LpL) for 15 min, 30 min and 45 min. Cell culture supernatants and lysate were collected and kept at -80°C. Human TGF-β1 protein expression was analyzed using enzyme-linked immunosorbent assay for quantitative detection of Human/Mouse TGF-β1 ELISA Ready-SET-Go! kit (#88-8350) from eBioscience, Inc. (San Diego, CA) according to manufacturer’s instructions. Microplates were scanned at a wavelength of 450 nm using a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). Supernatant concentration of activated TGF-β1 was evaluated following the manufacturers’ instructions based on standard curves. Each experiment was performed at least four times.

Western blotting

To study TGF-β/ATF3 signaling pathways, we performed Western Blot analysis. HAEC were grown to confluence in T-75 cell culture flasks and then treated as described above for 0.5, 1.5 or 3 h. After the incubation, cells were washed twice with PBS (without Ca and Mg), scraped with cold PBS and centrifuged at 3,000 rpm for 10 min at 4°C. Cell pellets were lysed in radio-immune precipitation assay (RIPA) buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, 1x Protease inhibitor cocktail set 1 (Calbiochem,
La Jolla CA), 1mM NaF, and 1mM Na3VO4. Protein concentration was determined with the bichinoic acid assay (Pierce), and equal amounts of proteins (50 μg) were separated by SDS-PAGE. The 11% total acrylamide, 2.75% crosslinker running gel was overlaid with a 4% total acrylamide, 2.75% crosslinker stacking gel and run at 4°C on a Hoefer SE-600 vertical tank chamber (Hoefer Scientific Instruments, San Francisco, CA) at 20 mA for an average of 5.5 h. Proteins were then transferred onto 0.2-μm polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA) which were subsequently blocked with 5% nonfat milk (Bio-Rad) for 1 h and then probed with either Smad2 (1:1000), p-Smad2/3 (1:200), Smad4 (1:200), p53 (1:200), ATF3 (1:200), c-Jun (1:200), p-c-Jun (1:1000), caspase-3 (3 μg/mL) or blotting control mouse monoclonal anti-β-actin (1:5,000) or nuclear loading control rabbit polyclonal anti-TBP (2 μg/mL) at 4°C overnight. Membranes were then incubated with HRP-conjugated secondary anti-mouse or anti-rabbit antibody (1:5,000) for 1 h. Blots were developed with the enhanced chemiluminescence detection system according to manufacturer’s instructions (Amersham). Protein expression levels were determined using a densitometer and Image Quant.

Immunofluorescence analysis

The cellular localization of endogenous as well as transiently expressed Smad4 and ATF3 was analyzed by fluorescence microscopy. HAEC were grown to confluence on fibronectin-coated 12-mm round coverslips placed in 24-well medical-grade polystyrene plates (BD Falcon) and were treated (n = 6 coverslips per treatment group) as described above. After treatment, cells were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature and then washed 3X with PBS. Cells then were permeabilized and blocked with Superblock (Pierce, Rockford, IL) containing 0.05% saponin for 30 min. Fixed cells were incubated with rabbit polyclonal anti-phospho-Smad2 (1:200 dilution) or Smad4 (1:100 dilution) or ATF3 (1:100 dilution) overnight and washed with 4X 10% superblock with 0.05% saponin to remove unbound antibody. Subsequently cells were treated with goat anti-rabbit antibody conjugated to Alexa fluor 488 (2 μg/mL) for 1 h, unbound material was removed as above. The nucleus was counterstained for 5 min with 4', 6-diamidino-2-phenylindole (DAPI) (1 μg/mL). Isotype controls were correspondingly run for all primary antibodies used in the study. After cells were mounted, they were evaluated and photographed with an Olympus BX61 system fluorescence microscope; but, p-Smad2 which was evaluated with Delta Vision Deconvolution Microscopy. The images shown are representative of at least six separate experiments. To assess the degree of nuclear accumulation of either Smad4 or ATF3, cells from five random view frames for six coverslips in each treatment group were counted as showing either fluorescing or non-fluorescing nuclei. Percent translocation was calculated as cells with green fluorescing nuclei divided by the total number of cells counted.

mRNA expression by quantitative RT-PCR (qRT-PCR)

Total RNA was extracted from cells in each of four T-25 flasks/per treatment group (Media, LpL, TGRL, and TGRL lipolysis products) using an RNeasy Mini Kit (Qiagen, Valencia, CA) including the DNA digestion step as described by the manufacturer. An aliquot equivalent to 5 μg of total RNA extracted from each sample was reverse-transcribed to obtain cDNA in a final volume of 21 μL using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). The real-time polymerase chain reaction (RT-PCR) with SYBR Green as fluorescent reporter was used to quantify the gene expression. All the gene specific primers (Table 1) were designed with Primer Express 1.0 software (Applied Biosystems) using the gene sequences obtained from previous data Affymetrix Probeset IDs [17]. Reactions were carried out in 384-well optical plates containing 25 ng RNA in each well. The quantity of applied RNA was
normalized by simultaneously amplifying cDNA samples with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers. The transcript levels were measured by real-time RT-PCR using the ABI ViiA™ 7 Real-Time PCR system (PE Applied Biosystems, Foster City, CA). The PCR amplification parameters were: initial denaturation step at 95°C for 10 min followed by 40 cycles, each at 95°C for 15 s (melting) and 60°C for 1 min (annealing and extension). A comparative C\textsubscript{T} method \cite{40} was used to calculate relative changes in gene expression determined from real-time quantitative PCR experiments (Applied Biosystems User Bulletin No.2 (P/N4303859). The threshold cycle, C\textsubscript{T}, which correlates inversely with the target mRNA levels, was measured as the cycle number at which the SYBR Green emission increases above a preset threshold level. The specific mRNA transcripts were expressed as fold difference in the expression of the specific mRNAs in RNA samples from the TGRL lipolysis product-treated cells compared to those from the control-treated cells.

**TUNEL Apoptosis assay**

To determine TGRL lipolysis induced apoptosis in endothelium of intact mouse carotid arteries, deeply anesthetized mice were perfused with T or TL through the left ventricle for 15 minutes and TUNEL assay was performed on paraffin embedded sections of carotid arteries. All experiments, IACUC protocol #15946, were approved by the Institutional Animal Care and Use Committee of the University of California, Davis. Animals were housed in a temperature and humidity controlled environment with a 12 hour light/dark cycle in the UC Davis Mouse Biology Program. For these studies, C57BL/6 mice were anesthetized with pentobarbital and a cannula was placed in the left ventricle of the heart. Perfusion was performed (N = 4 mice per group) with Media, TGRL (T), or TGRL lipolysis products (TL) at 1.5–2 mL per min for 15 min. Perfusion solutions were administered with 95% O\textsubscript{2}, 5% CO\textsubscript{2}. Tissues were then fixed by perfusion of 10% neutral buffered formalin for 15 minutes and sections of cervical musculature containing carotid arteries fixed overnight and embedded in paraffin. Paraffin sections (5 μm) were deparaffinized and rehydrated. TUNEL reaction was performed using DeadEndTM Fluorometric TUNEL system from Promega (Madison, WI) as described by the manufacturer.

### Table 1. Oligonucleotide sequence for each primer.

| Gene          | Primer sequence (5' - 3')        |
|---------------|----------------------------------|
| GAPDH         | Sense-CACCAACTGCTTAGCACCCC       |
|               | Antisense-TGGTCATGAGTCTTCCACG    |
| ATF3          | Sense-TCCTCCACCCGGTTAACACAAAA   |
|               | Antisense-AGAGGACCTGCCATCATGCT  |
| E-selectin    | Sense-CTGTCAATGAAAAATTTTCAGCA   |
|               | Antisense-TCAAGGGCTAGACAGTTTGG  |
| IL8           | Sense-CCCTCTCCACCCCAAATTTTATCA  |
|               | Antisense-TGGTCACACTCTCAATACACTCAG |
| IL6           | Sense-CTGCCCCAGTTAAGAGGTTC      |
|               | Antisense-CCGCCCAAGGCCCTCACAG   |
| NFkBIA (IkBA) | Sense-CTTTTGTTGTCCTTGGTTGCG    |
|               | Antisense-GCCATTACAGGGCTCTCGAG  |
| NFkB1 (NFκB)  | Sense-GTCAGAGGCTTGAGGAGGC       |
|               | Antisense-ATTCGCTCCGTTGAGGCCA   |
| JunB          | Sense-AATGGAACAGGCTTACACACGA    |
|               | Antisense-GGCTCGGTTCCAGGATTTGTAG |

\textcopyright\textsuperscript{2015} The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Tissues were counterstained with DAPI and cover slipped with Prolong gold. Cross sections of both internal and external carotid arteries from three levels of the cervical musculature were imaged with an Olympus BX61 fluorescence microscope. Photoshop CS was used to identify nuclei with enhanced fluorescein staining. A color range was selected using the eyedropper tool. When the bright green pixels associated with fluorescein-positive nuclei are selected, all nuclei containing this color range are automatically highlighted and are then counted manually. The images shown are representative of three separate experiments.

**Statistical Analysis.** Data for changes in gene expression obtained by qRT-PCR and protein expression were analyzed by GraphPad PRISM software (San Diego, CA). An unpaired student’s t test or two-way analysis of variance with repeated measures was used for comparisons between treatments. Differences with $P < 0.05$ were considered significant. Results are expressed as MEAN ± SEM.

**Results**

**TGRL Lipolysis Products Stimulate TGF-β1 Release**

To determine whether TGF-β1 release could be stimulated by TGRL lipolysis products, we analyzed both cell culture supernatants and cell lysates for TGF-β1 by ELISA. The rate of release of TGF-β1 into cell culture supernatants was significantly increased for TGRL lipolysis products (TL) treatments relative to media (M), or LpL (L) or TGRL (T) alone at 15 min (Fig 1). The time course of TGF-β1 release was short as no increase was evident release at 30 min, 45 min in S1A and S1B Fig. In addition, treatment with 10 μM TGF-β1 inhibitor (ALK) significantly decreased TGF-β1 release. TGF-β1 concentrations in the supernatant of cells treated with media trended higher than that in media without cells. TGF-β1 concentrations in cell free incubations of T, or TL were similar to that in cells treated with media alone. Cell treatment with M, L, T or ALK only slightly increased TGF-β1 compared to the M, T or TL only (without cells present). We did not detect any treatment-associated difference in cell lysate concentrations of TGF-β1.

**TGRL Lipolysis Products Increase Smad2 Phosphorylation**

To determine if TGRL lipolysis products could activate TGF-β family second messenger signaling, we determined Smad2 phosphorylation by western blotting, probing for Smad2 as well as p-Smad2 (Ser423/425). While Smad2 protein content was unchanged, we detected a significant increase (~ 3.5-fold) of p-Smad2 in cells treated with lipolysis products at 1.5 h (TL1.5) compared to media control (M) (Fig 2A). Phosphorylation of Smad2 was significantly reduced by the addition of ALK, SB 431542 (10 μM), an inhibitor of the activity of TGF-β1 activin receptor-like kinases (ALKs 4, 5, and 7). Treatment with T, L or 0.5 h of treatment with TGRL lipolysis products (TL0.5) did not increase p-Smad2. Immunofluorescence analysis also showed that phosphorylated Smad2 was in nucleus only following TL exposure (Fig 3A).

**TGRL Lipolysis Products Induce Smad4 Translocation to the Nucleus**

To determine whether TGRL lipolysis products could induce Smad4, we determined the Smad4 expression by western blotting, we detected an increase accumulation of Smad4 in the nucleus following exposure to TGRL lipolysis products (Fig 2B). Immunofluorescent labeling also confirmed the increase accumulation of the Smad4 in the nucleus, we characterized localization of Smad4. Our results demonstrated a Smad4 accumulation in the nucleus after treatment with TGRL lipolysis products at 1 h (Fig 3B). While nuclei in control cells treated with M, T or L alone were mostly dark and less green fluorescence, nuclei from cells treated with TL
at 1, 2 and 3 h had prominent green fluorescence. Accumulation of Smad4 in the nucleus at 3 h could be partially blocked by the addition of ALK, SB 431542 (10 μM).

Results of cell counts confirmed that significant numbers of cells accumulated Smad4 protein in their nucleus after only 1 h of treatment with lipolysis products, with approximately 67% of

Fig 1. TGRL lipolysis products release TGF-β1 at 15 min. The rate of TGF-β1 release is significantly increased for cells treated with TGRL (150 mg/dL) + LpL (2 U/mL) (TL) compared to cells treated with Media (M) or LpL alone (L) or TGRL alone (T), at 15 min. Addition of 10 μM of ALK to TL (TL+ALK) suppressed TGF-β1 released by TL. N = 4/treatment group, \( P < 0.05 \) as significant, * = TL compared to M, L, T or TL, # = TL+ALK compared to TL. TGF-β1 was not detected in M, T or TL only, in the absence of cells.

doi:10.1371/journal.pone.0145523.g001

Fig 2. Western Blots of Smad2 phosphorylation at 1.5 h and nuclear expression of Smad4 at 3 h. A) Smad2 and Phospho-Smad2 protein. Western Blot (a) and densitometry quantification (b) of Lysates from endothelial cells treated with TGRL (150 mg/dL) + LpL (2 U/mL) TL for 1.5 h (TL1.5) show significantly increased phosphorylation of Smad2 compared to cells treated with media (M), TGRL (T), LpL (L) or TL for 0.5 h (TL0.5). Addition of 10 μM of ALK, TGF-β receptor inhibitor, effectively blocks Smad2 phosphorylation (TL1.5+ALK). N = 3/treatment group, \( P < 0.05 \) as significant, * = TL1.5 compared to M, L, T, or TL0.5, # = TL1.5+ALK compared to TL1.5. B) Smad4 nuclear expression comparing M, L, T and TLA. Cytosolic fractions were also run on the same blot corresponding to the nuclear fraction. Levels of Smad4 were too low to detect when loaded at a proteins concentration equivalent to the level of protein loaded for the nuclear fraction. These lanes were removed for clarity. Addition of 10 μM of ALK, TGF-β receptor inhibitor, suppressed but did not completely abrogate lipolysis induced Smad4 nuclear accumulation.

doi:10.1371/journal.pone.0145523.g002
cells showing a nuclear localization of Smad4 (TL1h) compared to 16% for the media control (M) (Fig 3B). Smad4 nuclear staining was also observed after 2 and 3 h exposure to lipolysis products (TL2h, TL3h) (data not shown), but these increases were not significantly different from the 1 hour time point. Addition of the ALK, TGF-β receptor inhibitor SB 431542 (10 μM) significantly blocked the accumulation of Smad4 in the nucleus. While the inhibitor did not completely abrogate Smad4 accumulation, nuclear staining was apparent in 53% of inhibitor-treated cells compared with 92% for cells treated with lipolysis products alone for 3 h (Fig 3B).

TGRL Lipolysis Products Increase p53 Expression

To determine if expression of p53, a tumor suppressor protein and regulator of apoptosis was altered in HAEC exposed to lipolysis products, we performed western blots and analyzed
optical densities. After 1.5 h of treatment with TGRL lipolysis products (TL1.5), p53 expression was significantly increased (Fig 4), while the treatment with T or L did not significantly alter p53 expression compared to the media control group. Treatment of cells with lipolysis products for 3 h (TL3) resulted in reduced p53 protein expression compared to TL1.5 returning protein content to levels similar to those of the media control. The increase in p53 expression after treatment with lipolysis products (TL1.5) was significantly prevented by addition of ALK, SB 431542 (10 μM) (TL1.5+ALK) in S2 Fig.

To exclude the possibility of cross-reactivity of the antibody to lipolysis products, a control group was included for which TGRL plus LpL was incubated in flasks without cells and then processed and treated similar to other controls. As shown in S2 Fig, no immunoreactivity of the p53 antibody to TGRL lipolysis products was detected without cells (TL-).

**TGRL Lipolysis Products Activate Caspase-3**

To ascertain whether lipolysis products generated from co-incubation of TGRL with LpL induce the apoptotic cascade, we performed Western Blots for caspase-3 and calculated the expression of its active fragment. We found marked increase in expression of activated caspase-3 after 3 h treatment with lipolysis products (TL3) in Fig 5A and 5B. Treatment with ALK, SB 431542 (10 μM) completely blocked caspase-3 activation.

**TGRL lipolysis products activate apoptosis in mouse carotid arteries**

Our data demonstrate that caspase-3 protein expression was increased in *in vitro* HAEC exposed to TGRL lipolysis. To determine whether TGRL lipolysis activates apoptosis in intact arteries, we perfused mouse carotid arteries in situ with Media control, TGRL, or TGRL lipolysis products for 15 min. TUNEL staining showed apoptotic endothelial cells in carotid arteries treated with either TGRL or TGRL lipolysis products. TUNEL staining was not present in carotid artery endothelium from mice perfused with media alone (Fig 5C). Counts of endothelial cells showed carotid arteries perfused with TGRL alone had significantly increased numbers of apoptotic cells (40%) and TRGL lipolysis products further increased the proportion of apoptotic cells (65%) compared to medial alone (Fig 5C).

**Lipolysis Product-Induced Up-regulation of ATF3 is controlled by the TGF-β Receptor**

To assess whether TGRL lipolysis products induced ATF3 is downstream of TGF-β receptor activation, we performed qRT-PCR as well as western blots. Consistent with our previous results [17], we observed a dramatic 130-fold increase in mRNA expression for ATF3 after treatment with TGRL lipolysis products compared to cells treated with TGRL alone (Fig 6A). Addition of 10 μM ALK, SB 431542, an inhibitor to the activity of TGF-βR activin receptor-like kinases (ALKs 4, 5, and 7) (TL + ALK) significantly suppressed (50%) ATF3 mRNA expression compared to treatment with TGRL lipolysis products (TL) at 3 h.

Western blot analysis showed TGRL lipolysis products induced protein expression of ATF3 was also significantly suppressed by addition of 10 μM ALK inhibitor (TL+ALK) (Fig 6B). TGRL lipolysis products increased ATF3 expression significantly at 3 h compared to media, TGRL or LpL alone. The addition of a CD36 blocking antibody to the CD36 lipoprotein receptor was able to partially abolish the observed response of TGRL lipolysis products (Fig 6B).

After treatment with TGRL lipolysis products (TL) for 3 h, ATF3 was shown to be almost exclusively localized in the nucleus with 90% of cells counted as positively stained. Similarly, 70% of cells treated with human TGF-β1 (20 ng/mL) displayed brightly stained nuclei. The
addition of the TGF-β receptor inhibitor almost completely abrogated this response (TL+ALK) and only approximately 10% of cells showed nuclear accumulation (Fig 6C and 6D).

Moreover, HAEC treated with TL and anti TGF-β1 antibody (4 μg/mL) also significantly down-regulated mRNA expression of ATF3 (Fig 6D). Protein expression of ATF3 was also suppressed by TL with anti TGF-β1 (Fig 6F).

ATF3 Binding Partner c-Jun Expression is Regulated by the TGF-β Signaling

Our previous studies have indicated that TGRL lipolysis products up-regulated expression of transcription factor ATF3 and one of its binding partners c-Jun [17]. To determine whether this induction is downstream of TGF-β receptor activation, we performed western blots on cells treated with media, LpL, TGRL or TGRL lipolysis products (TL) or TL plus ALK, the TGF-β receptor inhibitor, (TL+ALK). While control groups (M, T or L) displayed no changes in c-Jun expression, treatment with TL significantly up-regulated c-Jun and p-c-Jun expression (Fig 7A). When the TGF-β receptor inhibitor was added (TL+ALK), expression levels of c-Jun decreased significantly and p-c-Jun expression was completely blocked by ALK inhibition. The immunofluorescence staining also showed that nuclear accumulation of p-c-Jun was suppressed when the TGF-β receptor inhibitor was added (TL+ALK) (Fig 7B).

Western blot analysis also showed that addition of anti TGF-β1 antibody (4 μg/mL) to TL also suppressed p-c-Jun protein expression (Fig 7C).

Transcription of E-selectin and IL-8 is Downstream of TGF-β

Our previous studies showed that TGRL lipolysis products are involved in the transcriptional regulation of the adhesion molecule E-selectin and the inflammatory cytokines IL-8 and IL-6.
While IL-8 up-regulation was dependent on activation of JNK and ATF3, IL-6 up-regulation was independent of these pathways. To demonstrate that ATF3’s regulatory role of E-selectin and IL-8 is dependent on prior lipolysis product-induced TGF-β receptor activation, HAEC were treated with TGRL, TGRL lipolysis products, or TL+ALK (TGF-β receptor inhibitor) for 3 h. TGF-β receptor inhibitor suppressed 69%, 60% and 75% of TGRL lipolysis products induced E-selectin (45-fold), IL-8 (48-fold) and JunB (7.5-fold) mRNA expression, respectively, compared to TGRL alone (Fig 8A). TGRL lipolysis product-induced up-regulation of the inflammatory cytokine IL-6 (12.8-fold), NFKBIA (5.8-fold) and NFKB1 (2.4-fold) were suppressed 50%, 47% and 42% by TGF-β1 receptor inhibitor (Fig 8B).

Additionally, anti TGF-β1 antibody also suppressed TGRL lipolysis products-induced E-selectin (46%) and IL-8 (30%) gene expression but not JunB (Fig 8C). The expression of
NFKBIA was suppressed 29% although IL-6 and NFKB1 were not suppressed by anti TGF-β1 antibody (Fig 8D).

**Discussion**

We have demonstrated that treatment with high-physiological levels of lipolysis products generated from TGRL isolated from healthy human volunteers, led to TGF-β secretion from cultured endothelial cells and subsequent autocrine TGF-β receptor activation, which, as far as we know, is a novel observation. However, there has been significant controversy over TGF-β’s role in the development of atherosclerosis [41, 42]. This cytokine displays a wide range of actions in all cell types that are known to be present in atherosclerotic lesions. Due to the array
of responses that TGF-β1 can elicit in different cell types, but also in the same cell type depending on serum levels, concentration, expression level of receptors and stage in the cell cycle, it has been difficult to put a distinctive label on this multi-functional cytokine. While initially presumed to be pro-atherogenic, since it was found at increased levels in vascular lesions [10, 43] and in aged aorta [44] and was shown to induce endothelial barrier dysfunction [45–47], additional studies have suggested that TGF-β is also anti-inflammatory and therefore anti-atherogenic. In endothelial cells specifically, TGF-β has been shown to inhibit cytokine-induced expression of adhesion proteins [48] as well as chemoattractants [49–51]. In the present study, we show that TGF-β1 released from HAEC cultures in response to treatment with lipolysis products can activate signaling cascades that lead to endothelial cell apoptosis. This finding is consistent with previous studies demonstrating TGF-β-induced endothelial cell death [24, 52].

While cell turnover occurs normally in healthy vessels, deranged or increased apoptosis of the endothelium has been associated with the development of atherosclerotic cardiovascular disease [1, 53]. This is thought to occur due to 1) an increased pro-coagulant state during endothelial apoptosis [54] and 2) the formation of membrane vesicles and blebs that contain biologically active oxidized phospholipids, which can induce monocyte adhesion [55]. This study as well as our previous findings [13, 17] suggests lipolysis products induce endothelial cell apoptosis independent from leukocytes or circulating proteins in blood.

Previous studies have demonstrated that modified lipoproteins, such as oxidized LDL, can stimulate TGF-β/Smad signaling and apoptosis in different cell types [56, 57] and that lipolysis of TGRL can generate oxylipids such as 13-HODE, the most prevalent oxylipid in oxidized

![Image](https://example.com/image.png)

**Fig 7.** The effect of the ALK 4, 5 and 7 inhibitor or anti TGF-β antibody on the TGRL lipolysis activated phosphorylation of c-Jun protein expression. HAEC were exposed to TGRL (T), TGRL lipolysis products (TL) or TL with 10 μM of inhibitor ALK (TL+ALK) for 3 h. TGF-β receptor inhibitor, ALK significantly suppressed: A) Western blot (a) and densitometry quantification (b) for p-c-Jun protein expression. N = 3, P<0.05. * = TL compared to T, # = TL+ALK compared to TL. B) Immunofluorescence images showing nuclear translocation of p-c-Jun. N = 3, Bar = 20 μm. anti TGF-β1 antibody (Ab) suppressed: C) Western blot (a) and densitometry quantification (b) p-c-Jun protein expression was trend toward suppressed significant. N = 3, P<0.05. * = TL or TL + anti TGF-β1 (TLA) compare to M.

doi:10.1371/journal.pone.0145523.g007
LDL [58]. We have shown that lipolysis products can similarly activate intracellular signaling cascades. Our findings indicate that this occurs through TGRL lipolysis product-mediated release of TGF-α1 and autocrine activation of receptors. We specifically report that the observed increase in TGF-α1 concentration in HAEC supernatants after treatment with lipolysis products translates into the activation of TGF-α1 receptors and Smad proteins. Upon ligand binding, type I (activin receptor-like kinases, ALKs) and type II TGF-α receptors form heteromeric complexes which facilitate the transphosphorylation of the type I receptor by the type II receptor. In most cells, TGF-α1 signals via TβRII and TβRI (also termed ALK5) to induce phosphorylation of Smad2. Our study demonstrates that lipolysis product-mediated release of TGF-α1 specifically activates TGF-α receptors leading to Smad2 phosphorylation. We also show that an inhibitor of the ALKs 4, 5, and 7 TGF-α type I receptor subtypes almost completely abrogates the induced phosphorylation of Smad2 and, blocks the translocation of Smad4 to the nucleus. A possible explanation of the partial attenuation of Smad4 translocation could be signaling via the endothelial-restricted type I receptor, ALK1 [59]. This receptor, in contrast to the ALK5 receptor, activates Smad1. Activated Smad1 also forms complexes with Smad4 with subsequent translocation to the nucleus.

Hyman et al. [24] showed that TGF-β causes apoptosis by stimulating the mitogen-activated protein kinase (MAPK) p38 in human umbilical vein or bovine capillary endothelial cells. Recent publications demonstrate that TGF-β1 can also trigger apoptosis via the mitochondrial pathway and the tumor suppressor protein p53. These studies showed that p53 expression is

![Image of Figure 8](image-url)

Fig 8. TGF-β receptor inhibitor or anti-TGF-β1 suppressed TGRL lipolysis products-induced pro-inflammatory gene expression. Treatment with lipolysis products increased pro-inflammatory gene expression at 3 h. Effect of 10 μM of inhibitor ALK (TL+ALK): A) mRNA expression of E-selectin, IL-8 and JunB expression was significantly suppressed by TGF-β receptor inhibitor. N = 3, P ≤ 0.05. * = TL compared to T, # = TL+ALK compared to TL. B) mRNA expression of IL-6, NFKBIA/IκBA and NFKB1/NFκB (p50) expression was also significantly suppressed by inhibitor. N = 3, P ≤ 0.05. * = TL compared to T, # = TL+ALK compared to TL. Effect of 4 μg/mL of anti TGF-β1 antibody: C) mRNA expression of E-selectin and IL-8 expression was significantly suppressed by anti TGF-β1 but not JunB. N = 3, P ≤ 0.05. * = TL compared to M, # = TL + anti TGF-β1 compared to TL.
up-regulated in various cell types after treatment with TGF-β1 [30, 48, 57, 60]. p53 activation can be induced by a number of stressors, including DNA damage [52, 61], oxidative stress [62, 63], osmotic shock [64], and cytokines [65–67]. Activation of p53 is characterized by two major events: 1) a marked increase of the half-life of p53 protein by escape from proteasome-dependent degradation, which leads to a quick accumulation of the protein and 2) the conversion of the conformation of the DNA-binding domain into a form with high affinity for target DNA, which allows p53 to play an active role as a transcription regulator [68]. In our study we were able to detect increased protein levels of p53 after 1.5 hours of treatment with lipolysis products and were able to demonstrate that the observed p53 induction was dependent upon TGF-β1 ligand/receptor interaction. The exact mechanisms whereby the activity of growth factors such as TGF-β1 intersect with p53 signaling is still not well understood. However, it is now established that p53 can physically interact with Smad2/3 to jointly regulate the transcription of several TGF-β target genes [28, 69, 70]. In contrast, other studies seem to indicate that TGF-β1 and p53 mediate distinctive apoptotic pathways [71, 72] due to different time courses of activity. Interestingly, p53 up-regulation was evident in earlier time points but not at 3 h post treatment correlating with short term TGF-β expression and suggesting downstream adaptation responses. Our findings demonstrate that for lipolysis product-induced apoptosis in HAEc cultures, activation of TGF-β receptors is required for p53 up-regulation and caspase-3 activation.

Our recent study showed the stress-inducible protein ATF3 [17], was impressively up-regulated in response to lipolysis products. Increasing evidence links this protein to the TGF-β signaling system [39] and also the regulation of endothelial cell apoptosis [21]. The present study was designed to determine, whether TGRl lipolysis products induce ATF3 via the TGF-β1 signaling cascade.

Our data demonstrate that the lipolysis product-induced up-regulation of ATF3, both at the mRNA and the protein level, is dependent on prior activation of the TGF-β receptor. While treatment with lipolysis products alone elicited a strong and impressive up-regulation of ATF3, pre-treatment with an inhibitor to the activity of TGF-β1 activin receptor-like kinases (ALKs 4, 5, and 7) and anti-TGF-β antibody remarkably inhibited this response both at the mRNA and trended in this direction relative to protein level. ATF3 protein expression was partially inhibited by CD36 receptor blocking antibody. CD36 is a glycoprotein and binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL contribute to important pathological processes highly relevant to atherosclerosis and thrombosis [73]. This finding data suggests that CD36 may recognize and bind specific oxidized phospholipid derived from TGRl lipolysis products that CD36 may participate in initiating the ATF3 related stress response. The interplay between and possible regulatory role of TGF-β and ATF3 is still not clear. Both proteins have been previously demonstrated to be potent inducers of endothelial cell apoptosis, were found to be highly expressed at sites of vascular lesions [21], and are both up-regulated in response to pathogenic stimuli like oxidized low density lipoprotein [21, 35, 56] or TNFα [74, 75]. In epithelial cells, ATF3 mRNA as well as protein levels showed an immediate and lasting induction in response to TGF-β [39]. The up-regulated expression was linked to binding of activated Smad2/3 and Smad4 proteins on a TGF-β-responsive region of the ATF3 promoter. A recent report by Jin [76] suggests that in mouse testis TGF-β activates both Smad signaling and non-Smad signaling pathways (MAPK). The authors suggest that the activated MAPK would then contribute to the up-regulation of transcription factors, such as ATF3 or c-Jun to regulate the expression of anti-oxidant enzymes. Since our previous work has linked lipolysis product treatment of endothelial cells to an increased generation of reactive oxygen species, it will be of future interest to pursue the notion that this phenomenon could be linked to prior...
TGF-β receptor activation/up-regulation of ATF3 and could possibly be blocked by the addition of TGF-β receptor inhibitors.

In addition to the regulation and suppression of antioxidant enzymes, ATF3 has also been implicated in the control of several other genes associated with the development of atherosclerosis, such as the expression of the adhesion molecule E-selectin and the cytokine IL-8 by our group [17] and others [77,78]. While the present study clearly shows that lipolysis products up-regulate those genes and this increase in expression depends on prior TGF-β receptor activation, another study reports that, at least in the case of E-selectin, ATF3 acts as a transcriptional repressor, not activator [77]. This difference in results might stem from the fact that ATF3 can form homodimers as well as heterodimeric complexes with other transcription factors, such as c-Jun, ATF2, gadd153/CHOP10, JunD and JunB [79] and thereby mediate different responses, depending on stimulus, cell type, and cell context.

As a transcription factor, ATF3’s activity depends on its ability to reach DNA binding sites and accumulate to the nucleus. Our immunofluorescence studies show that during treatment with lipolysis products, ATF3 quickly accumulates in the nucleus. A similar response was observed when cells were treated with TGF-β directly. Pre-treatment of the endothelial cell layer with an inhibitor of the TGF-β receptor lead to significant blockage of ATF3 nuclear localization. Previous reports have linked ATF3 up-regulation to a preceding or concurrent induction and phosphorylation of the transcription factor c-Jun and have shown that the increase in ATF3 expression can be blocked by knockdown of c-Jun [80–82]. While previous reports have demonstrated that ATF3 homodimeric complexes act as repressors for gene transcription, heterodimeric ATF3/c-Jun complexes seem to act as activators for gene transcription [78,83]. Additionally, known risk factors for the development of atherosclerotic cardiovascular disease can induce ATF3 in a c-Jun-dependent manner. Cai et al. (2000) and Zhang et al. (2001), for example, demonstrate that homocysteine leads to a rapid and sustained induction of c-Jun and precedes the induction of ATF3 [84,85]. Here, we show that treatment of HAEC with TGRL lipolysis products leads to increased phosphorylation of c-Jun, which occurred concurrently with our observed up-regulation of ATF3. It remains to be tested whether there is a physical interaction between ATF3 and c-Jun to form previously reported heterodimeric complexes [78,83], that may act as transcription factors to regulate the transcription of target genes.

The lipolysis product-induced increase in c-Jun expression was in a manner similar to ATF3, blocked by the addition of an inhibitor of the TGF-β receptor or anti-TGF-β antibody. This suggests that both c-Jun and ATF3 are under the regulatory control of the TGF-β/Smad signaling cascade. A study by Jin et al. also suggests a link between Smad signaling and c-Jun/ATF3 and shows that silencing Smad2 with siRNA partially attenuates expression of c-Jun and ATF3 [76]. The direct effects of Smad2 on c-Jun and ATF3 have not been investigated.

In our previous study [17] we found ATF3 expression was necessary for induction of some, but not all, pro-inflammatory responses to lipolysis product treatment. In the present study inhibition of the TGF-β receptor (ALK) suppressed pro-inflammatory gene expression related to AP-1 signaling (E-selectin, IL-8) and NFkB signaling (IL-6, NFKB1, NFKBIA) by TGRL lipolysis products. In contrast, findings including lack of IL-6, NFKB1 (NFxB), and JunB responsiveness and decreased NFKB1 (IkBα) by anti-TGF-β antibody suggest that anti-TGF-β antibody only inhibited JNK pathway but not NFkB signaling in response to lipolysis products. Both the antibody blocking of TGF-β and the use of the ALK receptor inhibitor lend support to the involvement to a TGF-β signaling pathway in the cellular response to lipolysis products.

To determine the relevance of our in vitro findings to intact arteries, we performed a similar experiment by perfusing mouse arteries in situ. Our findings demonstrate the induction of apoptosis by lipolysis products in intact arteries. In addition, perfusion of TGRL alone induced a
significant percentage of apoptotic cells suggesting that LpL expressed in endothelium from intact arteries is sufficient to elicit lipolysis product induced signaling.

In summary, we have made novel observations that TGRL lipolysis products stimulate release of active TGF-β1 and autocrine activation of the Smad signaling cascade in endothelial cells. We confirm that lipolysis of postprandial lipids induces the up-regulation of the stress protein ATF3 in human aortic endothelial cells and this up-regulation is under the regulatory control of the TGF-β/Smad signaling cascade both at the mRNA as well as the protein level. Our study demonstrates that ATF3 mediated TGRL lipolysis induced inflammation and apoptosis is dependent on the TGF-β/Smad signaling pathway (Fig 9). While the exact interplay between the ATF3 and TGF-β signaling network is still largely unknown and represents a fertile area for further investigation, the present study points to the TGF-β receptor as a potential target for intervention to block the up-regulation of stress proteins, like ATF3, a master regulator of endothelial cell inflammatory responses.

Supporting Information

S1 Fig. TGRL lipolysis products release TGF-β1. A) TGF-β1 release at 30 min. B) TGF-β1 release at 45 min. The rate of TGF-β1 release is no changed for cells treated with with Media (M) or LpL alone (L) or TGRL alone (T), TGRL (150 mg/dL) + LpL (2 U/mL) (TL) or addition of 10 μM of ALK to TL (TL+ALK), at 30 min or 45 min. N = 4/treatment group. (TIF)

S2 Fig. p53 protein expression by TGRL lipolysis products was suppressed by TGF-β receptor inhibitor, ALK. Western Blot (a) and densitometry quantification (b) for p53. The increase in p53 expression after treatment with lipolysis products (TL1.5) was prevented by addition of ALK4, 5 and 7 inhibitor (TL1.5+ALK). No immunoreactivity of lipolysis products only was detected to the p53 antibody (TL-). Decreased p53 expression in response to lipolysis products in TL1.5+ALK cells was statistically significant. N = 3/treatment group, * = P≤0.05. (TIF)
S1 ARRIVE Checklist.
(PDF)

Acknowledgments
The authors gratefully thank Jennifer Rutkowsky for recruiting human subjects and TGRL isolation, and Victoria Tan for assistance in western bolting.

Author Contributions
Conceived and designed the experiments: LE HHA. Performed the experiments: LE TN MWL KN HHA. Analyzed the data: LE TN HHA. Contributed reagents/materials/analysis tools: DWW JCR. Wrote the paper: LE HHA. Reviewed and revised the paper: MWL DWW JCR.

References
1. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001; 33(9):1673–90. PMID: 11549346.

2. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol. 1995; 147(2):251–66. PMID: 7639325; PMCID: PMC1869820.

3. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liu G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995; 147(2):267–77. PMID: 7639326; PMCID: PMC1869810.

4. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995; 91(11):2703–11. PMID: 7758173.

5. Du XL, Sui GZ, Stockklauser-Farber K, Weiss J, Zink S, Schwippert B, et al. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia. 1998; 41(3):249–56. PMID: 9541141.

6. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000; 93(1–3):65–77. PMID: 11033054.

7. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol. 1998; 275(2 Pt 2):H568–76. PMID: 9853446.

8. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002; 80(12):753–69. PMID: 12483461.

9. Morley N, Kuksis A. Positional specificity of lipoprotein lipase. J Biol Chem. 1972; 247(20):6389–93. PMID: 5076762.

10. Nilsson-Ehle P, Eggertud P, Belfrage P, Olivecrona T, Borgstrom B. Positional specificity of purified milk lipoprotein lipase. J Biol Chem. 1973; 248(19):6734–7. PMID: 4355505.

11. Wang L, Sapuri-Butti AR, Aung HH, Parikh AN, Rutledge JC. Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am J Physiol Heart Circ Physiol. 2008; 295(1):H237–44. PMID: 18487440; PMCID: PMC2494756. doi: 10.1152/ajpheart.01366.2007

12. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res. 2009; 50(2):204–13. PMID: 18812596; PMCID: PMC2636918. doi: 10.1194/jlr.M700505-JLR2000

13. Eiselein L, Wilson DW, Lame MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol. 2007; 292(6):H2745–53. PMID: 17259442.

14. Norata GD, Grigore L, Raselli S, Seccomandi PM, Hamsten A, Maggi FM, et al. Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. J Mol Cell Cardiol. 2006; 40(4):484–94. PMID: 16516917.

15. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2007; 193(2):321–7. PMID: 17055512.
16. Ting HJ, Stice JP, Schaff UY, Hui DY, Rutledge JC, Knowlton AA, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res. 2007; 100(3):381–90. PMID: 17234968.

17. Aung HH, Lame MW, Gohil K, An CI, Wilson DW, Rutledge JC. Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2013; 33(9):2088–96. PMID: 23868936; PMCID: PMC3921073. doi: 10.1161/ATVBHA.113.301375

18. Feng J, Sun Q, Wu T, Lu J, Qu L, Sun Y, et al. Upregulation of ATF3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression. Int J Clin Exp Pathol. 2013; 6(10):2064–70. PMID: 24133584; PMCID: PMC3796228.

19. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006; 441(7090):173–8. PMID: 16688168.

20. Akram A, Han B, Masoom H, Peng C, Lam E, Litvack ML, et al. Activating transcription factor 3 confers protection against ventilator-induced lung injury. Am J Respir Crit Care Med. 2010; 182(4):489–500. PMID: 20413626; PMCID: PMC2937241. doi: 10.1164/rcrm.200906-0925OC

21. Nawa T, Nawa MT, Adachi MT, Uchimura I, Shimokawa R, Fujisawa K, et al. Expression of transcriptional repressor ATF3/LRF1 in human atherosclerosis: colocalization and possible involvement in cell death of vascular endothelial cells. Atherosclerosis. 2002; 161(2):281–91. PMID: 11888510

22. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685–700. PMID: 12809600.

23. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993; 8(1):1–9. PMID: 8448037.

24. Hyman KM, Seghezzi G, Pintucci G, Stellari G, Kim JH, Grossi EA, et al. Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase. Surgery. 2002; 132(2):173–9. PMID: 12219008.

25. Pollman MJ, Naumovski L, Gibbons GH. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation. 1999; 99(15):2019–26. PMID: 10209007.

26. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004; 29(5):265–73. PMID: 15103065.

27. Chiarugi V, Magnelli L, Cinelli M. Complex interplay among apoptosis factors: RB, p53, E2F, TGF-beta, cell cycle inhibitors and the bcl2 gene family. Pharmacol Res. 1997; 35(4):257–61. PMID: 9264039.

28. Cordenonsi M, Dupont S, Maretto S, Insinga A, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell. 2003; 113(3):301–14. PMID: 12732139.

29. Sola S, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry. 2004; 43(26):8429–38. PMID: 15222754.

30. Zhang S, Ekman M, Thakur N, Bu S, Davoodpour P, Grimsby S, et al. TGFbeta1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle. 2006; 5(23):2787–95. PMID: 17172861.

31. Inoue K, Zama T, Kamimoto T, Aoki R, Ikeda Y, Kimura H, et al. TNFalpha-induced ATF3 expression is mediated by ATM and p53. J Biochem. 2004; 135(5):500. PMID: 15840021.

32. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A. 1991; 88(9):3720–4. PMID: 1827203; PMCID: PMC51524.

33. Watson A, Eilers A, Lallemand D, Kyriakis J, Rubin LL, Ham J. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J Neurosci. 1998; 18(2):751. PMID: 9107159.
37. Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000; 14 (13):1996–2007. PMID: 11039884.

38. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. The Journal of clinical investigation. 1998; 102(9):1682–9. PMID: 9802882; PMCID: PMC569116.

39. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003; 11(4):915–26. PMID: 12718878.

40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–8. PMID: 11846609.

41. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004; 24(3):399–404. PMID: 14699019.

42. Singh NN, Ramji DP. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev. 2006; 17(6):487–99. PMID: 17056295.

43. Nikol S, Isner JM, Pickering JG, Keamery M, Leclerc G, Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. The Journal of clinical investigation. 1992; 90(4):1582–92. PMID: 1328302; PMCID: PMC443206.

44. Wang M, Zhao D, Spinetti G, Zhang J, Jiang LO, Pintus G, et al. Matrix metalloproteinase 2 activation of transforming growth factor beta-1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol. 2006; 26(7):1503–9. PMID: 16690877.

45. Birukova AA, Adyshev D, Gorchov B, Birukov KG, Verin AD. ALK5 and Smad4 are involved in TGF-beta1-induced pulmonary endothelial permeability. FEBS Lett. 2005; 579(18):4031–7. PMID: 16004987.

46. Clements RT, Minnear FL, Singer HA, Keller RS, Vincent PA. RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am J Physiol Lung Cell Mol Physiol. 2005; 288(2):L294–306. PMID: 15475381.

47. Lu Q, Harrington EO, Jackson H, Morin N, Shannon C, Rounds S. Transforming growth factor-beta1-induced endothelial barrier dysfunction involves Smad2-dependent p38 activation and subsequent RhoA activation. J Appl Physiol. 2006; 101(2):375–84. PMID: 16645187.

48. Rorke EA, Zhang D, Choo CK, Eckert RL, Jacobberger JW. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression. Exp Cell Res. 2000; 259(1):149–57. PMID: 10942587.

49. Chen CC, Manning AM. TGF-beta 1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. Cytokine. 1996; 8(1):58. PMID: 8742067.

50. Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR. Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol. 1996; 157(1):360–8. PMID: 8683138.

51. Weiss JM, Cuff CA, Berman JW. TGF-beta downmodulates cytokine-induced monocyte chemoattractant protein (MCP)-1 expression in human endothelial cells. A putative role for TGF-beta in the modulation of TNF receptor expression. Endothelium. 1999; 6(4):291–302. PMID: 10475092.

52. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984; 4(9):1689–94. PMID: 6092932; PMCID: PMC366974.

53. McLaughlin R, Kelly CJ, Kay E, Boucher-Hayes D. The role of apoptotic cell death in cardiovascular disease. Ir J Med Sci. 2001; 170(2):132–40. PMID: 11491059.

54. Bombei T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997; 89(7):2429–42. PMID: 9116287.

55. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Wiltzum JL, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002; 22(1):101–7. PMID: 11785468.

56. Ding G, van Goor H, Ricardo SD, Orlovski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int. 1997; 51(1):147–54. PMID: 8995728.

57. Teramoto T, Kiss A, Thorgeirsson SS. Induction of p53 and Bax during TGF-beta 1 induced apoptosis in rat liver epithelial cells. Biochem Biophys Res Commun. 1998; 251(1):56–60. PMID: 9790906.

58. Lenz ML, Hughes H, Mitchell JR, Via DP, Guyton JR, Taylor AA, et al. Lipid hydroperoxide and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. J Lipid Res. 1990; 31(6):1043–50. PMID: 2373954.
59. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005; 65(3):599–608. PMID: 15664386.

60. Edlund S, Bu S, Schuster N, Aspenstrom P, Heuchel R, Heldin NE, et al. Transforming growth factor-beta1 (TGF-beta)–induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell. 2003; 14(2):529–44. PMID: 12589052; PMCID: PMC149990.

61. Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 1991; 51(16):4279–86. PMID: 1868448.

62. Long X, Goldenthal MJ, Marin-Garcia J. Oxidative stress enhances phosphorylation of p53 in neonatal rat cardiomyocytes. Mol Cell Biochem. 2007; 303(1–2):167–74. PMID: 17457521.

63. Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M, et al. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by poly-l-lysin kinase-3. J Biol Chem. 2001; 276(39):36194–9. PMID: 11447225.

64. Dmitrieva N, Kultz D, Michea L, Ferraris J, Burg M. Protection of renal inner medullary epithelial cells from apoptosis by hypertonic stress-induced p53 activation. J Biol Chem. 2000; 275(24):18243–7. PMID: 10747924.

65. Donato NJ, Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem. 1998; 273(9):5067–72. PMID: 9478957.

66. Gottlieb WH, Watson JM, Rezai A, Johnson M, Martinez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol. 1994; 170(4):1121–8; discussion 8–30. PMID: 8166195.

67. Ladiwala U, Li H, Antel JP, Naibantoglu J. p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. J Neurochem. 1999; 73(2):605–11. PMID: 10428056.

68. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000; 77:81–137. PMID: 10549356.

69. Dupont S, Zacchigna L, Adorno M, Soligo S, Volpin D, Piccolo S, et al. Convergence of p53 and TGF-beta signaling networks. Cancer Lett. 2004; 213(2):129–38. PMID: 15327827.

70. Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem. 2007; 282(8):5661–9. PMID: 17204482.

71. Francis JM, Heyworth CM, Spooner E, Pierce A, Dexter TM, Whetton AD. Transforming growth factor-beta1 induces apoptosis independently of p53 and selectively induces expression of Bcl-2 in multipotent hematopoietic cells. J Biol Chem. 2000; 275(50):39137–45. PMID: 10993901.

72. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene. 1994; 9(6):1791–8. PMID: 8183578.

73. Silverstein RL, Li W, Park YM, Rahaman SO. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Transactions of the American Clinical and Climatological Association. 2010; 121:206–20. PMID: 20697562; PMCID: PMC2917163.

74. Lu D, Sivaprasad U, Huang J, Shankar E, Morrow S, Basu A. Protein kinase C-epsilon protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis. 2007; 12(10):1893–900. PMID: 17668322.

75. Simeonova PP, Gallucci RM, Huiderman T, Wilson R, Kommineni C, Rao M, et al. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol. 2001; 177(2):112–20. PMID: 11740910.

76. Jin MH, Hong CH, Lee HY, Kang HJ, Han SW. Enhanced TGF-beta1 is involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced oxidative stress in C57BL/6 mouse testis. Toxicol Lett. 2008; 178(3):202–9. PMID: 18467041. doi: 10.1016/j.toxlet.2008.03.015

77. Nawa T, Nawa MT, Cai Y, Zhang C, Uchimura I, Narumi S, et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun. 2000; 275(2):406–11. PMID: 10964678.

78. Chen BP, Liang G, Whelan J, Hai T. ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem. 1994; 269(22):15819–26. PMID: 7515060.

79. Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 2001; 273(1):1–11. PMID: 11483355.
80. Liang G, Wolfgang CD, Chen BP, Chen TH, Hai T. ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem. 1996; 271(3):1695–701. PMID: 8576171.

81. Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C, et al. Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience. 2008; 151(3):771–9. PMID: 18178318. doi: 10.1016/j.neuroscience.2007.10.057

82. Jack GD, Cabrera MC, Manning ML, Slaughter SM, Potts M, Helm RF. Activated stress response pathways within multicellular aggregates utilize an autocrine component. Cell Signal. 2007; 19(4):772–81. PMID: 17127033.

83. Hsu JC, Bravo R, Taub R. Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol. 1992; 12(10):4654–65. PMID: 1406655.

84. Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S, et al. Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood. 2000; 96(6):2140–8. PMID: 10979959.

85. Zhang C, Kawauchi J, Adachi MT, Hashimoto Y, Oshiro S, Aso T, et al. Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. Biochem Biophys Res Commun. 2001; 289(3):718–24. PMID: 11726207.